[Treatment of infectious complications affecting the skin and soft tissues with cefpodoxime proxetil]

Area of Science:

• Infectious Diseases
• Dermatology
• Pharmacology

Context:

• Skin and soft tissue infections (SSTIs) are common and can lead to significant morbidity.
• Surgical intervention is often necessary for SSTIs, but antimicrobial therapy plays a crucial role in management.
• Third-generation cephalosporins offer broad-spectrum activity against common bacterial pathogens implicated in SSTIs.

Purpose:

• To evaluate the efficacy and safety of cefpodoxime proxetil in treating diverse skin and soft tissue infections.
• To assess the clinical outcomes of patients receiving cefpodoxime proxetil as part of their treatment regimen for SSTIs.
• To determine the appropriate duration and dosage of cefpodoxime proxetil for managing these infections.

Summary:

• A study involving 20 patients with various SSTIs, including phlegmon, panaritium, post-laparotomy infections, abscesses, cheilitis, and olecranon bursitis, was conducted.
• Patients received surgical treatment (incision, evacuation, drainage) combined with cefpodoxime proxetil (200 mg every 12 hours for 6-9 days).
• Microbiological samples were collected, and cefpodoxime proxetil serum levels were monitored. All 20 patients achieved a full recovery.

Impact:

• Demonstrates the clinical effectiveness of cefpodoxime proxetil as a treatment option for a range of skin and soft tissue infections.
• Highlights the successful integration of this third-generation cephalosporin with surgical management for improved patient outcomes.
• Provides evidence supporting the use of cefpodoxime proxetil in ambulatory surgical settings for managing common bacterial infections.